The Agency for Medical Research (ABM) has announced the outcome of the Open Competition for non-commercial clinical trials and research experiments (ABM/2024/1). As a result of the competition, which ran from March to May 2024, funding with a total value of more than PLN 278 million was awarded to 21 projects. The competition attracted 75 applications, 65 of which met the merit evaluation criteria and were further analyzed.
ABM: Competition for non-commercial research has been awarded
Published Nov. 6, 2024 11:52
The selected projects focus on improving treatment and diagnostic standards in various areas of medicine, covering innovative approaches to therapy and diagnostics that can contribute to significant benefits for patients and the health care system in Poland.
Among the projects, research in cardiology, psychiatry, neurology, neonatology and pediatrics occupy a special place. They are aimed at developing new therapeutic strategies for the treatment of cardiovascular diseases such as malignant hypertension, coronary artery disease and heart failure, as well as analyzing the effectiveness of robotic surgery and various pharmacotherapy options. Innovative approaches are also present in the treatment of treatment-resistant depression. The project is investigating the effectiveness of psilocybin as an adjunctive therapy, given in combination with or after withdrawal from SSRI drugs, in patients with drug-resistant depression. The study aims to develop new treatment standards for this group of patients
Some projects focus on novel therapies and diagnostic tools in genetic and pediatric diseases, using new surgical techniques such as robotic surgery or advanced diagnostic methods such as whole exome sequencing in newborns. In the areas of neurology and immunology, research is underway on probiotic therapies as supportive treatments for multiple sclerosis, which can help improve quality of life and slow disease progression. The effectiveness of supportive therapies is also being studied in chronic and rare diseases such as Duchenne muscular dystrophy, immunodeficiencies and Fabry disease.
- By investing in research based on sound science, as well as in projects that address urgent clinical needs, we are laying the foundation for lasting change in many areas of medicine - from cardiology and neurology to genetics and oncology. Our goal is not only to implement new treatments, but also to better understand the mechanisms of many diseases, enabling a more precise and personalized approach to each patient. With financial support from the Medical Research Agency, the selected projects have the potential to revolutionize existing treatment patterns and healthcare management in Poland, offering more effective, safe and sustainable solutions. This exceptional support for researchers and doctors is proof that our country can and will play a significant role in the global arena of medical innovation. We are confident that the results of this research will, in the long term, translate into real health benefits for Polish patients, as well as a reduction in healthcare costs, through the use of more precise and preventive treatments.
- concluded Prof. Wojciech Fendler, president of ABM.
Source: press release
